Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies - ACR Meeting Abstracts

Por um escritor misterioso

Descrição

Background/Purpose: Although the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is used to assess the activity of axial disease in patients (pts) with PsA, only one of its questions is specific to axial symptoms. Alternatively, the Ankylosing Spondylitis Disease Activity Score (ASDAS) excludes assessment of enthesitis, gives less weight to peripheral activity and is considered […]
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis - ACR Meeting Abstracts
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
To What Extent Do Clinical Features of PsA Predict Achievement of Minimal Disease Activity at Week 24: A Post Hoc Analysis of the Phase III Clinical Trial Program of Guselkumab in a
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
PDF) Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Treat to Target in Spondyloarthritis: Myth or Reality? - European Medical Journal
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Treat to Target in Spondyloarthritis: Myth or Reality? - European Medical Journal
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Canadian Rheumatology Association Meeting Quebec City Convention Centre Quebec City, Quebec, Canada February 8–11, 2023
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies - The Lancet Rheumatology
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
PDF) Management of psoriatic arthritis: a consensus opinion by expert rheumatologists
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Plenary Presentations - 2021 - International Journal of Rheumatic Diseases - Wiley Online Library
Performance of BASDAI vs. ASDAS in Evaluating Axial Involvement in Patients  with PsA Treated with Guselkumab: Pooled Analysis of Two Phase 3 Studies -  ACR Meeting Abstracts
Canadian Rheumatology Association Meeting Quebec City Convention Centre Quebec City, Quebec, Canada February 8–11, 2023
de por adulto (o preço varia de acordo com o tamanho do grupo)